SOBI

Inspired by caring, powered by science

At Sobi, we improve the lives of people with rare diseases. As a multinational biopharmaceutical company, we bring innovative therapies in the areas of hematology, immunology, and specialty care to enable a better life for people.

We focus our rare strength in immunology, where we have a portfolio of specialty drugs, in hematology, an area in which, in addition to being recognized leaders in hemophilia, we have expanded our portfolio in recent years with new therapies for the treatment of rare blood diseases, and in onco-hematology. We raise treatment standards, develop scientific evidence to support them, commit to sustainable access, and provide assistance to people with rare diseases while exploring new opportunities worldwide.

To learn more about our commitment, click here https://www.sobi.com/italy/it and visit our social channels on LinkedIn, Instagram, Facebook, and YouTube.

SOBI

Sobi is a multinational biopharmaceutical company specializing in solutions dedicated to changing the lives of people with rare diseases. Sobi offers sustainable access to innovative therapies in fields such as hematology, onco-hematology, immunology, and specialty indications. Currently, the company has about 1,800 employees in Europe, North America, the Middle East, and Asia. In 2023, Sobi recorded a revenue of 22.1 billion Swedish kronor. Sobi shares are listed on Nasdaq Stockholm (STO: SOBI).